Orforglipron
First oral non-peptide GLP-1 receptor agonist (Eli Lilly); Phase 3 obesity program.
Scientific Overview
Orforglipron (LY3502970) is Eli Lilly's small-molecule, non-peptide GLP-1R agonist. Unlike oral semaglutide it does not require SNAC absorption enhancers or fasted dosing. Phase 2 obesity (2023) showed up to 14.7% weight loss at 36 weeks. Phase 3 ATTAIN and ACHIEVE programs read out in 2025.
Key Research Benefits
- ✓Oral once-daily dosing
- ✓No food/water restrictions
- ✓Weight loss comparable to injectable GLP-1s in Phase 2
Potential Side Effects
Research Protocols
Common DosagesInvestigational
“Phase 3 dose range”
Dose Calculator
🧮 Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 4.80 mL on a U-100 syringe
Explore Orforglipron
Orforglipron by goal
Read Orforglipron's profile filtered through specific research goals.
Molecular Profile
Quick Reference
- Status
- Research Compound
- Category
- Metabolic
- Common Dosage
- 12 -> 36 mg
- Daily, oral
Strictly for research purposes. Not for human consumption.
Related tools
Medical Disclaimer
Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.